Objective: The paper is to improve drug security for children, to provide suggestions for the adjustment of special drugs for children in the national catalog of drugs covered by basic medical insurance. Methods: Through the combination of medical insurance catalog retrieval, literature retrieval, the adjustment process of special drugs for children in the four editions of medical insurance catalog from2017to2021was compared to understand the progress, problems of special drugs for children, provide suggestions for further improving the adjustment of special drugs for children in the national medical insurance catalog. Results: The types of special drugs for children increased by51.52%, the number of special drugs with national negotiation for children increased from0to11. However, in the2021version of the medical insurance catalogue, the proportion of special drugs for children in western drugs was only3.36%, which was still insufficient. The development of appropriate dosage forms for special drug use in children is slow, the description of usage, dosage is not precise, accurate enough, the actual needs of children are not fully considered, the suitability of drugs is insufficient. Conclusions: It is suggested to take incentive measures to promote the research, development, production of special drugs for children, enrich the dosage forms, specifications, tastes of special drugs for children, increase the number of special drugs for children, increase the adjustment weight of the suitability of special drugs for children, improve the supply guarantee of children's drugs
Key words
children’s medicine /
national catalog of drugs /
supply guarantee of medicine /
appropriateness
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
References
[1] 朱雅玲,张彬.人口结构变动下中国消费的未来趋势:基于第七次全国人口普查数据的分析[J].陕西师范大学学报(哲学社会科学版),2021,50(04):149-162.
[2] 王晓雅. 基于可及性角度的儿童用药品现状研究[D].江西:江西中医药大学,2020.
[3] 国务院.关于印发中国妇女发展纲要和中国儿童发展纲要的通知(国发〔2021〕16号)[EB/OL].(2021-09-27)[2022-09-10].http://www.gov.cn/xinwen/2021-09/27/content_5639545.htm.
[4] 国家药品监督管理局药品审评中心.中国新药注册临床试验进展年度报告(2021年)[EB/OL].(2022-06-07)[2022-09-10].https://www.cde.org.cn/main/news/viewInfoCommon/1839a2c931e1ed43eb4cc7049e189cb0.
[5] 王树月,贾玉芹,陈明珠,等.2014—2019年国产儿童用药批准情况分析[J].中国药物评价,2021,38(02),169-173.
[6] 李丰杉,余勤.儿童用药研发及儿科临床试验的国际发展和国内现状[J].中国新药杂志,2020,29(17):1933-1938.
[7] 殷潇. 我国药物供应保障政策效应研究[D].武汉:武汉大学,2018.
[8] 国家药物和卫生技术综合评估中心.关于发布心血管病、抗肿瘤、儿童药品临床综合评价技术指南的通知[EB/OL].(2022-06-29)[2022-09-10].http://www.nhei.cn/nhei/znfb/202206/c01d87a290664b01-bf42a9dad769d69f.shtml.
[9] 中华人民共和国人力资源和社会保障部.关于印发国家基本医疗保险、工伤保险和生育保险药品目录(2017年版)的通知(人社部发〔2017〕15号)[EB/OL].(2017-02-23)[2022-09-10].http://www.mohrss.gov.cn/SYrlzyhshbzb/dongtaixinwen/buneiyaowen/201702/t20170223_266787.html.
[10] 国家医疗保障局,中华人民共和国人力资源和社会保障部.关于印发《国家基本医疗保险、工伤保险和生育保险药品目录(2019年)》的通知(医保发〔2019〕46号)[EB/OL].(2019-08-20)[2022-09-10].http://www.nhsa.gov.cn/art/2019/8/20/art141664.html.
[11] 国家医疗保障局,中华人民共和国人力资源和社会保障部.关于印发《国家基本医疗保险、工伤保险和生育保险药品目录(2020年)》的通知(医保发〔2020〕53号)[EB/OL].(2020-12-28)[2022-09-10].http://www.nhsa.gov.cn/art/2020/12/28/art_37_4220.html.
[12] 国家医疗保障局,中华人民共和国人力资源和社会保障部.关于印发《国家基本医疗保险、工伤保险和生育保险药品目录(2021年)》的通知(医保发〔2021〕50号)[EB/OL].(2021-12-03)[2022-09-10].http://www.nhsa.gov.cn/art/2021/12/3/art_104_7438.html.
[13] 郭志烨,李玲玲,褚智君,等.某院门诊儿童常用药品说明书中儿童用药信息标注情况调查分析[J].儿科药学杂志,2022,28(06):33-37.
[14] 陈春. 近10年青岛市9家医院安乃近临床使用中安全性分析[J].医药导报,2021,40(04):477-481.
[15] 周虹,于晓佳,安卓玲,等.基于CiteSpace软件的奥司他韦安全性研究可视化分析[J].临床药物治疗杂志,2021,19(09):41-45.
[16] 李文君,卢梦情,徐蔼琳,等.国内外不同年龄段儿童用药剂型的比较与思考[J]. 中国医院药学杂志,2019,39(21),2236-2239.
[17] 牛振喜,邢亚兵,马姝丽.儿童用药依从性及其影响因素分析[J].儿科药学杂志,2021,28(01),31-34.
[18] 冯燕. 我院儿童口服药物剂型现状及改良措施[J].中国现代药物应用,2017,11(12):140-141.
[19] 孟鑫如,霍记平,史卫忠,等.《国家基本医疗保险、工伤保险和生育保险药品目录》与《WHO儿童基本药物示范目录》的比较[J].医药导报,2019,38(10),1379-1383.
[20] 施萍. 儿童年龄分期及胎儿期、围生期保健重点[J].中国社区医师,2011,27(42):28.
[21] 赖勇杰,傅润宸,刘思彤,等.国内外儿童用药依从性研究现状及趋势—基于CiteSpace的可视化分析[J].中国医院药学杂志,2021,41(20):2054-2060.
[22] 国家药品监督管理局药品审评中心.关于发布《儿童用药(化学药品)药学开发指导原则(试行)》的通告(2020年第67号)[EB/OL].(2020-12-31)[2022-09-10].https://www.cde.org.cn/main/news/viewInfoCommon/95102a5facaf8fd4430d0916a24eab53.
[23] 国家药品监督管理局药品审评中心.关于公开征求《儿童用药口感设计与评价的技术指导原则(公开征求意见稿)》意见的通知[EB/OL].(2022-06-17)[2022-09-10].https://www.cde.org.cn/main/news/viewInfoCommon/ae21267106ed09c6c8c86f47e98c447a.
[24] 中共中央,国务院.关于深化医疗保障制度改革的意见[EB/OL].(2020-02-25)[2022-09-10].http://www.gov.cn/zhengce/2020-03/05/content_5487407.htm.
[25] 李钊,陈盛,周绿林,等.国家组织药品集中带量采购的实践操作问题与优化对策[J].中国卫生经济,2022,41(07),60-64.
